<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>63(7)</volume><submitter>Burggraaff CN</submitter><pubmed_abstract>We aimed to determine the added value of baseline metabolic tumor volume (MTV) and interim PET (I-PET) to the age-adjusted international prognostic index (aaIPI) to predict 2-y progression-free survival (PFS) in diffuse large B-cell lymphoma. Secondary objectives were to investigate optimal I-PET response criteria (using Deauville score [DS] or quantitative change in SUV&lt;sub>max&lt;/sub> [ΔSUV&lt;sub>max&lt;/sub>] between baseline and I-PET4 [observational I-PET scans after 4 cycles of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone administered in 2-wk intervals with intensified rituximab in the first 4 cycles [R(R)-CHOP14]). &lt;b>Methods:&lt;/b> I-PET4 scans in the HOVON-84 (Hemato-Oncologie voor Volwassenen Nederland [Haemato Oncology Foundation for Adults in the Netherlands]) r</pubmed_abstract><journal>Journal of nuclear medicine : official publication, Society of Nuclear Medicine</journal><pagination>1001-1007</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9258573</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>&lt;sup>18&lt;/sup>F-FDG PET Improves Baseline Clinical Predictors of Response in Diffuse Large B-Cell Lymphoma: The HOVON-84 Study.</pubmed_title><pmcid>PMC9258573</pmcid><pubmed_authors>Burggraaff CN</pubmed_authors><pubmed_authors>de Keizer B</pubmed_authors><pubmed_authors>van der Holt B</pubmed_authors><pubmed_authors>Eertink JJ</pubmed_authors><pubmed_authors>Zijlstra JM</pubmed_authors><pubmed_authors>Arens AIJ</pubmed_authors><pubmed_authors>HOVON Imaging Working Group and the HOVON Lymphoma Working Group</pubmed_authors><pubmed_authors>Pieplenbosch S</pubmed_authors><pubmed_authors>Lugtenburg PJ</pubmed_authors><pubmed_authors>Heymans MW</pubmed_authors><pubmed_authors>Wiegers SE</pubmed_authors><pubmed_authors>de Vet HCW</pubmed_authors><pubmed_authors>Boellaard R</pubmed_authors><pubmed_authors>Hoekstra OS</pubmed_authors></additional><is_claimable>false</is_claimable><name>&lt;sup>18&lt;/sup>F-FDG PET Improves Baseline Clinical Predictors of Response in Diffuse Large B-Cell Lymphoma: The HOVON-84 Study.</name><description>We aimed to determine the added value of baseline metabolic tumor volume (MTV) and interim PET (I-PET) to the age-adjusted international prognostic index (aaIPI) to predict 2-y progression-free survival (PFS) in diffuse large B-cell lymphoma. Secondary objectives were to investigate optimal I-PET response criteria (using Deauville score [DS] or quantitative change in SUV&lt;sub>max&lt;/sub> [ΔSUV&lt;sub>max&lt;/sub>] between baseline and I-PET4 [observational I-PET scans after 4 cycles of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone administered in 2-wk intervals with intensified rituximab in the first 4 cycles [R(R)-CHOP14]). &lt;b>Methods:&lt;/b> I-PET4 scans in the HOVON-84 (Hemato-Oncologie voor Volwassenen Nederland [Haemato Oncology Foundation for Adults in the Netherlands]) r</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Jul</publication><modification>2025-04-22T10:10:06.169Z</modification><creation>2025-04-05T23:30:13.519Z</creation></dates><accession>S-EPMC9258573</accession><cross_references><pubmed>34675112</pubmed><doi>10.2967/jnumed.121.262205</doi></cross_references></HashMap>